Vimarsana
Biggest News Aggregation in the World

Deyo Weinstein News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Deyo Weinstein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Deyo Weinstein Today - Breaking & Trending Today

Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual Meeting - Vimarsana News

Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual Meeting

Published: May 6, 2022

06.05.2022 - SP-102 (SEMDEXATM) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular pain, and it contains no preservatives, surfactants, solvents, or particulates.The study met its ...

Source: wallstreet-online.de
Related Topics:
United StatesNew YorkSan DiegoUniversity Of Illinois At ChicagoPalo AltoJaisim ShahBrian CooleyNebojsa Nick KnezevicJeffrey ChiDeyo WeinsteinDecisions Resources GroupSemnur Pharmaceuticals IncVickers Vantage CorpAmerican Society Of NeuromodulationDepartment Of AnesthesiologyScilex Holding CompanyPivotal Trialc Le Ar ProgramScilex Pharmaceuticals IncCollege Of MedicineCompany Or ScilexIllinois Society Of Interventional Pain PhysiciansIllinois Masonic Medical CenterPractice Research Clinical RheumatologyDrug AdministrationSorrento Therapeutics Inc
Scilex, a Sorrento Company, Announces Pivotal Phase 3 - Vimarsana News

Scilex, a Sorrento Company, Announces Pivotal Phase 3

Published: May 6, 2022

SP-102 (SEMDEXATM) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular...

Source: globenewswire.com
Related Topics:
United StatesNew YorkSan DiegoPalo AltoJaisim ShahJeffrey ChiDeyo WeinsteinDecisions Resources GroupSemnur Pharmaceuticals IncPractice Research Clinical RheumatologyDrug AdministrationVickers Vantage CorpScilex Holding CompanySorrento Therapeutics IncSorrento CompanyPivotal Trialc Le Ar ProgramScilex Pharmaceuticals IncCompany Or ScilexHolding CompanySorrento TherapeuticsLumbar Epidural AnalgesiaText ViewCombined CompanySecurities ActPrivate Securities Litigation Reform Act
Scilex Holding Company, a Majority-Owned Subsidiary of - Vimarsana News

Scilex Holding Company, a Majority-Owned Subsidiary of

Published: March 17, 2022

Combined company expected to have a pro forma equity value post-money of approximately $1.64 billion, subject to potential adjustment, and with up to $140...

Source: globenewswire.com
Related Topics:
United StatesNew YorkSan DiegoPalo AltoSteven Ross JohnsonJaisim ShahHenry JiJeffrey ChiDeyo WeinsteinMailis GagnonSemnur Pharmaceuticals IncVickers Vantage CorpScilex Holding CompanyPaul HastingsCelularity IncVickers Venture Fund Vi Plan Pte LtdPivotal Trialc Le Ar ProgramScilex Pharmaceuticals IncCompany Or ScilexCenters For DiseaseDrug AdministrationExchange CommissionVickers Venture Fund Vi Pte LtdSorrento Therapeutics IncVickers Vantage